Table 1.
Overview of patients enrolled within the clinical trial
|
Total LSCD | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| No. | AGE | SEX | LSCD etiology | Type | Follow-up (months) | VA before | VA after | Tx Post LEC TX | Result |
|
1 |
44 |
M |
Chemical burn |
allo* auto |
41 |
CF (0.014) |
CF (0.014) |
PK |
Failed |
|
2 |
45 |
F |
Chemical burn |
auto |
43 |
HM (0.005) |
0,05 |
- |
AS, FS |
|
4 |
45 |
M |
Chemical burn |
auto |
31 |
CF (0.014) |
<0,05 |
- |
Failed |
|
5 |
6 |
M |
Chemical burn |
auto |
31 |
HM (0.005) |
LP (0) |
PK |
Failed |
|
6 |
27 |
M |
Aniridia |
allo** |
27 |
0.053 |
0.1 |
PK |
AS, FS |
|
7 |
70 |
F |
Corneal ulcer |
auto |
25 |
LP (0) |
HM (0.005) |
PK |
AS, FS |
|
8 |
29 |
M |
Chemical burn |
auto |
25 |
<0,05 |
HM (0.005) |
- |
Failed |
|
10 |
33 |
M |
Chemical burn |
auto |
19 |
LP (0) |
LP (0) |
- |
Failed |
|
11 |
63 |
M |
Iatrogenic |
auto |
19 |
HM (0.005) |
HM (0.005) |
- |
AS |
|
13 |
31 |
F |
Aniridia |
allo** |
48 |
CF (0.014) |
0.2 |
PK |
AS, FS |
|
14 |
16 |
F |
Kniest syndrome |
auto |
6 |
LP (0) |
HM (0.005) |
- |
AS |
|
15 |
6 |
M |
Keratitis |
auto |
5 |
LP (0) |
LP (0) |
- |
Failed |
|
16 |
48 |
M |
Chemical burn |
auto |
4 |
CF (0.014) |
0.125 |
- |
AS, FS |
|
17 |
79 |
M |
Trauma |
auto |
4 |
CF (0.014) |
CF (0.014) |
- |
AS |
|
18 |
42 |
F |
Viral keratitis |
auto |
18 |
LP (0) |
HM (0.005) |
PK |
AS, FS |
|
Partial LSCD | |||||||||
|
No. |
AGE |
SEX |
LSCD Etiology |
Type |
Follow-up (months) |
VA before |
VA after |
Tx Post LEC TX |
Result |
|
3 |
57 |
F |
Iatrogenic |
auto |
39 |
0.15 |
0,16 |
- |
AS, FS |
|
9 |
44 |
F |
Keratitis, uveitis |
auto |
24 |
CF (0.014) |
0.15 |
PK |
AS, FS |
| 12 | 47 | M | Trauma | auto | 18 | 0.2 | 0.9 | - | AS, FS |
The table shows the subject code, age, sex, etiology of LCSD (Limbal Stem Cell Deficency), type of donor (allo* = allogenic cadaveric, allo** = from living related donor), the follow-up, visual acuities pre and post op (LP = light perception, CF = counting fingers, HM = hand movements) surgical interventions following LEC TX (Limbal epithelial cell transplant) particularly PK (penetrating keratoplasty) procedures and the vision at most recent follow-up (AS = anatomical success, FS = functional success).